Chris Boerner, Bristol Myers Squibb COO
September 15, 2023 11:29 AM EDTUpdated September 22, 04:22 AM
Pharma
Manufacturing

Bris­tol My­er­s' man­u­fac­tur­ing shut­down means low­er-than-ex­pect­ed Q3 sales for Abec­ma

Anna Brown

News Reporter

Bris­tol My­ers Squibb and 2sev­en­ty bio said this week that a man­u­fac­tur­ing shut­down will trans­late to low­er-than-ex­pect­ed sales for their CAR-T cell ther­a­py Abec­ma in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

As­traZeneca takes $753M charge on aban­doned com­ple­ment drug from Alex­ion deal

Pfiz­er hires No­var­tis on­col­o­gy ex­ec to steer its can­cer am­bi­tions

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

J&J, In­tra-Cel­lu­lar quick­ly sealed $14B deal as three oth­ers passed on buy­ing the neu­ro drug­mak­er

As­traZeneca of­fers some de­tail on Chi­na probe, reaf­firms com­mit­ment to that mar­ket

A service from the Financial Times